<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(7)</volume><submitter>Pervez Lali S</submitter><pubmed_abstract>This study explores the enhancement of oral bioavailability, dissolution rate, and solubility of weakly water-soluble fluoroquinolone antibiotic, ofloxacin (OFL), by solid dispersion (SD) formulation prepared using the spray drying technique. Hydrophilic polymers; hydroxypropyl methylcellulose (HPMC) and xanthan gum (XNG) were used as carriers. FT-IR spectroscopy indicated hydrogen bonding between OFL and the polymer's backbone. DSC and PXRD analyses revealed a transformation from the crystalline to the amorphous state. SEM images revealed reduced particle size and changed surface morphology, which are favorable for solubility improvement. The &lt;i>in vitro&lt;/i> drug release studies, performed in simulated gastric conditions (pH 6.8) showed a significant improvement in the drug release, 97.88% and 82.34% for HPMC-based (O-H) and XNG-based (O-X) SDs, respectively, as compared to only 59.2% for unprocessed OFL. Further, &lt;i>in vivo&lt;/i>, kinetics reported in a validated HPLC-UV method in rabbits showed an impressive &lt;i>C&lt;/i> &lt;sub>max&lt;/sub> (O-H: 4.33 µg mL&lt;sup>-1&lt;/sup>; O-X: 4.12 µg mL&lt;sup>-1&lt;/sup>; OFL: 1.8 µg mL&lt;sup>-1&lt;/sup>) and  prolonged &lt;i>t&lt;/i> &lt;sub>1&lt;/sub>/&lt;sub>2&lt;/sub> (8 h &lt;i>vs.&lt;/i> 5 h). Thus demonstrating a significant enhancement in bioavailability in the rabbit model. The SDs produced with HPMC and XNG represent a promising strategy to improve the solubility and &lt;i>in vivo&lt;/i> performance of OFL, which may translate to improved therapeutic efficacy.</pubmed_abstract><journal>RSC advances</journal><pagination>6048-6060</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12848879</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Engineering ofloxacin bioavailability through spray-dried HPMC and xanthan gum-based solid dispersions: enhanced solubility and therapeutic efficacy.</pubmed_title><pmcid>PMC12848879</pmcid><pubmed_authors>Shaaban IA</pubmed_authors><pubmed_authors>Sher M</pubmed_authors><pubmed_authors>Abbas A</pubmed_authors><pubmed_authors>Hussain MA</pubmed_authors><pubmed_authors>Naeem-Ul-Hassan M</pubmed_authors><pubmed_authors>Haseeb MT</pubmed_authors><pubmed_authors>Khaled Sendy B</pubmed_authors><pubmed_authors>Pervez Lali S</pubmed_authors><pubmed_authors>Fatima A</pubmed_authors><pubmed_authors>Alhoshani FM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Engineering ofloxacin bioavailability through spray-dried HPMC and xanthan gum-based solid dispersions: enhanced solubility and therapeutic efficacy.</name><description>This study explores the enhancement of oral bioavailability, dissolution rate, and solubility of weakly water-soluble fluoroquinolone antibiotic, ofloxacin (OFL), by solid dispersion (SD) formulation prepared using the spray drying technique. Hydrophilic polymers; hydroxypropyl methylcellulose (HPMC) and xanthan gum (XNG) were used as carriers. FT-IR spectroscopy indicated hydrogen bonding between OFL and the polymer's backbone. DSC and PXRD analyses revealed a transformation from the crystalline to the amorphous state. SEM images revealed reduced particle size and changed surface morphology, which are favorable for solubility improvement. The &lt;i>in vitro&lt;/i> drug release studies, performed in simulated gastric conditions (pH 6.8) showed a significant improvement in the drug release, 97.88% and 82.34% for HPMC-based (O-H) and XNG-based (O-X) SDs, respectively, as compared to only 59.2% for unprocessed OFL. Further, &lt;i>in vivo&lt;/i>, kinetics reported in a validated HPLC-UV method in rabbits showed an impressive &lt;i>C&lt;/i> &lt;sub>max&lt;/sub> (O-H: 4.33 µg mL&lt;sup>-1&lt;/sup>; O-X: 4.12 µg mL&lt;sup>-1&lt;/sup>; OFL: 1.8 µg mL&lt;sup>-1&lt;/sup>) and  prolonged &lt;i>t&lt;/i> &lt;sub>1&lt;/sub>/&lt;sub>2&lt;/sub> (8 h &lt;i>vs.&lt;/i> 5 h). Thus demonstrating a significant enhancement in bioavailability in the rabbit model. The SDs produced with HPMC and XNG represent a promising strategy to improve the solubility and &lt;i>in vivo&lt;/i> performance of OFL, which may translate to improved therapeutic efficacy.</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-11T06:01:21.99Z</modification><creation>2026-06-11T03:12:01.728Z</creation></dates><accession>S-EPMC12848879</accession><cross_references><pubmed>41613229</pubmed><doi>10.1039/d5ra06222e</doi></cross_references></HashMap>